Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial (Q44553655)
Jump to navigation
Jump to search
scientific article published on 18 August 2003
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial |
scientific article published on 18 August 2003 |
Statements
1 reference
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial (English)
1 reference
1 reference
1 reference
Christopher B Granger
1 reference
Kenneth W Mahaffey
1 reference
Witold Ruzyllo
1 reference
Pierre Theroux
1 reference
Thomas G Todaro
1 reference
W Douglas Weaver
1 reference
Jose C Nicolau
1 reference
Thomas G Filloon
1 reference
Christopher F Mojcik
1 reference
COMPLY Investigators
1 reference
18 August 2003
1 reference
1 reference
Identifiers
1 reference